Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3705 - 3712 of 12104 results
4 Ways A Biden Election Could Swing SEC Priorities
October 21, 2020| News
USCIS Announces Premium Processing Fee Increase Effective October 19; Planned Premium Processing Expansions Remain Pending
October 20, 2020| Blog| Viewpoint
Monthly TCPA Digest — October 2020
October 20, 2020| Article| Viewpoint
TCPA Litigation Update — District Court Rules TCPA Unconstitutional from 2015 to 2020
October 20, 2020| Article| Viewpoint
TCPA Regulatory Update — A Busy FCC Continues to Implement the TRACED Act; Public Notice on Flu Vaccines During the Pandemic
October 20, 2020| Article| Viewpoint
COVID-19 Telecommuting Tax and Leave Issues for Employers
October 20, 2020| Blog| Viewpoint
Bioethics in a Pandemic: Final Framework for Equitable Allocation of a COVID-19 Vaccine
October 20, 2020| Blog| Viewpoint
FDA Provides Update on Pre-Cert Program and Launches Digital Health Center of Excellence
October 19, 2020| Blog| Viewpoint
News & Press Releases
Mintz Advises Oppenheimer & Co. and Initial Purchasers in $475M Convertible Senior Notes Offering by WisdomTree
August 19, 2025
Mintz represented Oppenheimer & Co., as sole book-running manager, and Craig-Hallum Capital Group and Northland Securities, as co-managers, in the private placement of $475 million aggregate principal amount of 4.625% Convertible Senior Notes due 2030 issued by WisdomTree, Inc (NYSE: WT) (“WisdomTree”). The notes were sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.
Mintz Advises Underwriters in Assembly Biosciences' $175 Million Underwritten Offering and Concurrent Private Placement
August 18, 2025
Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.
Mintz advised the underwriters in connection with the $173 million public offering by Ondas Holdings Inc. of 53,084,000 shares of its common stock, which includes 6,924,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|